What is the success rate?

After 36 months, only six patients progressed to surgery. The remaining 20 patients reported average ODI and VAS improvements from 56.7 ± 3.6 and 82.1 ± 2.6 at baseline to 17.5 ± 3.2 and 21.9 ± 4.4 after 36 months

• • Pettine, K.A., Suzuki, R.K., Sand, T.T. et al. Autologous bone marrow concentrate intradiscal injection for the treatment of degenerative disc disease with three-year follow-up. International Orthopaedics (SICOT) 41, 2097–2103 (2017). https://doi.org/10.1007/s00264-017-3560-9

Data were analyzed from 14 patients (8 men and 6 women; mean age, 33.8 years). The average follow-up period was 10 months. Following treatment, no patient experienced adverse events or significant narrowing of disc height. The mean pain scores before treatment (VAS, 7.5±1.3; RDQ, 12.6±4.1) were significantly decreased at one month, and this was generally sustained throughout the observation period (6 months after treatment: VAS, 3.2±2.4, RDQ; 3.6±4.5 and 12 months: VAS, 2.9±2.8; RDQ, 2.8±3.9; p<0.01, respectively)

• Intradiscal Injection of Autologous Platelet-Rich Plasma Releasate to Treat Discogenic Low Back Pain: A Preliminary Clinical Trial, Koji Akeda¹, Kohshi Ohishi², Koichi Masuda³, Won C. Bae⁴, Norihiko Takegami¹, Junichi Yamada¹, Tomoki Nakamura¹, Toshihiko Sakakibara⁵, Yuichi Kasai⁵, Akihiro Sudo^1, Asian Spine J. 2017 Jun; 11(3): 380–389.